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Infections caused by multidrug-resistant Acinetobacter baumannii constitute a major life-threatening problem worldwide, and
early adequate antibiotic therapy is decisive for success. For these reasons, rapid detection of antibiotic susceptibility in this
pathogen is a clinical challenge. Two variants of the Micromax kit were evaluated for a rapid detection in situ of susceptibility or
resistance to meropenem or ciprofloxacin, separately, in 322 clinical isolates. Release of the nucleoid is the criterion of suscepti-
bility to the beta-lactams (carbapenems), whereas diffusion of DNA fragments emerging from the nucleoid characterizes the
quinolone activity. All the susceptible and resistant strains were correctly categorized in 100 min according to theMIC results
and CLSI criteria. Thus, our technology is a promising tool for rapid identification of carbapenem and quinolone resistance of A.
baumannii strains in hospital settings.
One of the most formidable challenges in practical medicine isthe progressive worldwide increase of multidrug-resistant
Acinetobacter baumannii strains. This opportunistic pathogen
shows an alarming ability for nosocomial spread and persistence,
causing a wide variety of serious infections, mostly in immuno-
compromised hospitalized patients, and is associated with an ele-
vated mortality rate. The most common illness caused by A. bau-
mannii is severe pneumonia that is frequently ventilator
associated, but the pathogen also causes infections in the blood-
stream, central nervous system, urinary tract, skin and soft tissues,
and bone (9, 15).
The first-line treatment for serious A. baumannii infection re-
lies on a carbapenem antibiotic such as imipenem ormeropenem.
These are beta-lactams that affect peptidoglycan synthesis by in-
teracting with the active center of penicillin-binding proteins
(PBPs), with inhibition of the transpeptidation reaction (12).
Alarmingly, resistance to carbapenems is increasingly common.
This is duemainly to the production of chromosome- or plasmid-
encoded carbapenemases but also to changes in outer membrane
porins, multidrug efflux pumps, or alteration in the affinity or
expression of PBPs (5). These mechanisms often work in concert,
resulting in multidrug-resistant strains (15). Other treatment op-
tions include the use of quinolones like ciprofloxacin or levofloxa-
cin, which induce DNA double-strand breaks by trapping the
DNA gyrase and/or topoisomerase IV on the DNA, resulting in
DNA fragmentation (6). Nevertheless, resistance to quinolones is
also emerging, through mutations mainly in the quinolone resis-
tance-determining region (QRDR) within gyrA and parC genes
(20, 21, 22), which interfere with the target binding, but resistance
is also mediated by multidrug efflux pumps (5).
Standard antibiograms require nearly 24 h or even longer to
yield results after the bacterial isolate has been identified. Some-
times, while waiting for results from the microbiology laboratory,
physicians must implement empirical antibiotic therapy. Never-
theless, inappropriate empirical antimicrobial therapy is associ-
ated with increased mortality, and it is emphasized that early, ad-
equate antibiotic therapy is essential to improve outcomes (7, 11,
13). Moreover, inadequate use of antibiotics contributes to the
emergence and spread of drug resistance and increases toxic ef-
fects and health care costs. Rapid and reliable antimicrobial resis-
tance testing should be of great relevance for selection of the most
appropriate antibiotic therapy and optimized use of antimicrobi-
als. For example, a fast assessment of carbapenem status may en-
sure a most favorable treatment in case of microbe susceptibility,
avoiding misuse of antibiotics that should be reserved for cases of
proven resistance. However, given the great facility to develop
multidrug resistance in A. baumannii, a rapid evaluation of car-
bapenem and quinolone susceptibility should be of great interest.
In fact, a recent nationwide multicenter study in Spain revealed
thatmore than 93%and 81%ofA. baumannii isolates showed lack
of sensitivity to ciprofloxacin and to imipenem, respectively (data
not shown).
We have developed a procedure to assess DNA integrity in
bacteria, which has been validated as a rapid and simple assay for
determination of susceptibility or resistance to quinolones in
Escherichia coli (8, 17, 19). Cells trapped in an agarosemicrogel on
a slide are incubated with a lysing solution to remove the cell wall
from all the cells in the population; the nucleoids are then visual-
ized under fluorescence microscopy after staining with the fluo-
rochrome SYBR Gold. Using our procedure, DNA fragmentation
induced by quinolones is visualized as DNA spots that diffuse
peripherally from the nucleoid. The greater the DNA fragmenta-
tion, the greater the number of DNA spots and the width of the
circular diffusion area around the central residual core. In the case
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of resistance to quinolones, the nucleoids appear intact, with lim-
ited spreading of DNA fiber loops (17).
More recently, the procedure wasmodified to evaluate cell wall
integrity, i.e., the efficacy of antibiotics that affect peptidoglycan
synthesis (18). For this purpose, the lysis must be adapted to affect
only those bacteria whose cell walls have been damaged by the
antibiotic. If the bacterium is susceptible, the weak cell wall is
removed by the lysing solution so that the nucleoid contained
inside the bacterium is released and spread. In the case of a resis-
tant strain, bacteria are practically unaffected by the lysis solution
and so do not liberate the nucleoid, which retains its usual shape.
In this straightforward report, we evidence the usefulness of
using both technical variants to rapidly determine the susceptibil-
ity or resistance of A. baumannii to carbapenems, using mero-
penem as the antibiotic model, and ciprofloxacin.
MATERIALS AND METHODS
Bacterial strains. Three hundred twenty-two A. baumannii consecutive
isolates obtained at University Hospital A Coruña (collected from 2001 to
2011) and from the bacterial collection of the Spanish Network for Re-
search in Infectious Diseases were analyzed. Repetitive extragenic palin-
dromic (REP)-PCRwas performed in some cases to rule out clonality (2).
Moreover, two reference strains obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA), ATCC 17978 and ATCC 19606,
showing meropenem and ciprofloxacin susceptibility, were also assayed.
Specific A. baumannii strains with defined carbapenem and ciprofloxacin
resistance mechanisms were also used as controls. The MICs were deter-
mined by automatedmicrodilution (MicroScanWalkaway; Siemens) and
confirmed by Etest (AB Biodisk; bioMérieux) according to the manufac-
turer’s instructions and following CLSI criteria for antibiotic susceptibil-
ity categorization.
DNA fragmentation assay. Determination of DNA fragmentation
and cell wall integrity was carried out as a blind procedure, without
knowledge of the MICs. Two variants of the Micromax kit for fluores-
cence microscopy (Halotech DNA SL, Madrid, Spain), Micromax-Q and
Micromax WG-, were employed to evaluate the integrity of the nucleoid
and of the cell wall, respectively. The only difference between the two
assays lies in the lysing solution.
Bacteria were routinely grown in Mueller-Hinton agar at 37°C for 24
h. A colony was grown with aeration and shaking in Mueller-Hinton
broth at 37°C for 90 min. Then, the culture was diluted to an optical
density at 600 nm (OD600) of 0.1 in Mueller-Hinton broth. They were
then incubated at 37°C in 200-l tubes, withmeropenem at 0, 4, 8, and 16
g/ml and with ciprofloxacin at 0, 1, 2, and 4 g/ml for 60 min, in a final
volume of 30l. These concentrations were chosen according to the CLSI
breakpoint concentrations of susceptibility, intermediate resistance, and
resistance (3). The kit includes 0.5-ml snap cap microcentrifuge tubes
containing gelled aliquots of low-melting-point agarose. The tube was
placed in a water bath at 90 to 100°C for about 5 min to melt the agarose
completely and then placed in a water bath at 37°C. Thirty microliters of
the diluted sample was added to the tube and mixed with the melted
agarose (the final concentration was 5 to 10 million microorganisms/ml).
A 10-l aliquot of the sample-agarose mixture was pipetted onto a pre-
coated slide and covered with an 18- by 18-mm coverslip. The slide was
placed on a cold plate in the refrigerator (4°C) for 5 min to allow the
agarose to produce a microgel with the trapped intact cells inside. The
coverslip was removed gently, and the slide was immediately immersed
horizontally in 10 ml of the specific lysing solution for 5 min at room
temperature for those bacteria incubated with meropenem and at 37°C
for those incubated with ciprofloxacin. The slide was washed horizontally
in a tray with abundant distilled water for 3 min, dehydrated by incubat-
ing horizontally in cold (20°C) ethanol of increasing concentration
(70%, 90%, and 100%) for 3 min each, and air dried in an oven, and the
DNA was stained with 25 l of the fluorochrome SYBR Gold (Molecular
Probes, Eugene, OR) diluted 1:200 in Tris-borate-EDTA (TBE) buffer
(0.09M Tris-borate, 0.002M EDTA, pH 7.5) for 2 min in the dark, with a
glass coverslip. After a brief wash in phosphate buffer (pH 6.88) (Merck,
Darmstadt, Germany), a 24- by 60-mmcoverslipwas added, and the slides
were visualized under fluorescence microscopy.
RESULTS AND DISCUSSION
According to the procedure, a strain is categorized as susceptible
to meropenem when the nucleoids start to appear to spread fol-
lowing incubation with the drug at the CLSI breakpoint concen-
tration of susceptibility (4 g/ml), i.e., at 4, 8, and 16 g/ml.
Intermediate strains begin to release the nucleoids at the CLSI
breakpoint dose of intermediate resistance (8g/ml), i.e., at 8 and
16g/ml. Resistant strains never liberate the nucleoids, or they do
so only after incubation with the drug at the CLSI breakpoint dose
of resistance (16 g/ml). In relation to ciprofloxacin, a strain is
susceptible when it shows DNA fragmentation from incubation
with the drug at the CLSI breakpoint dose of susceptibility (1
g/ml), i.e., at 1, 2, and 4 g/ml. An intermediate strain reveals
fragmented DNA after incubation at the CLSI breakpoint dose of
intermediate resistance (2 g/ml), i.e., at 2 and 4 g/ml. In a
resistant strain, nucleoids always appear intact or appear frag-
mented only after treatment with the drug at the CLSI breakpoint
concentration of resistance (4 g/ml).
Susceptible strains and those with recognized mechanisms of
reduced susceptibility or resistance were initially tested as control
strains. For meropenem assays, commercial ATCC 19606 (MIC,
0.25 g/ml) and ATCC 17978 (MIC, 0.5 g/ml) were selected as
susceptible strains. Strains producing serine -lactamases oxacil-
linases OXA-24 (strain RYC 52763/97; MIC, 256 g/ml) (1),
OXA-58 (MIC, 16 g/ml), and OXA-23 (MIC, 16 g/ml) were
chosen as resistant strains. An intermediate strain with MIC of 8
g/ml was selected, i.e., strain JC10/01 (pAT-RA-34s) (4). Repre-
sentative images are presented in Fig. 1. Susceptible strains
showed nucleoid spreading at 4, 8, and 16 g/ml, and intermedi-
ate strains revealed release of nucleoids after 8 and 16 g/ml,
whereas resistant strains did not reveal spreading of nucleoids at
any dose, except those that liberated some nucleoids at anMIC of
16 g/ml.
For ciprofloxacin, the ATCC 17978 strain was used as suscep-
tible control (MIC,0.125g/ml). A clinical isolate intermediate
strain (MIC, 2g/ml) and a resistant strainwithmutations result-
ing in changes at codon 83 for gyrA (TCA¡TTA) and at codon 80
for parC (TCG¡TTG) (MIC, 64 g/ml) (where underlining in-
dicates a changed base) were also used as controls. The susceptible
strain showed nucleoids with fragmentedDNA after incubation at
1, 2, and 4 g/ml, and the intermediate strain showed DNA frag-
mentation only after incubation at 2 and 4 g/ml, whereas nucle-
oids always appeared intact in the resistant strain (Fig. 2).
Once the procedure had been successfully assayed in control
strains, 322 clinical isolates were processed by the Micromax kits.
MIC determination by automated microdilution and confirmed
by Etest according to CLSI criteria was considered the gold stan-
dard method. According to the MICs and the CLSI criteria, 39
isolates were susceptible to both meropenem and ciprofloxacin,
37 were susceptible to meropenem and resistant to ciprofloxacin,
only 1 isolate was resistant to meropenem and susceptible to cip-
rofloxacin, and 159 were resistant to both meropenem and cipro-
floxacin. Regarding intermediate strains, 85 isolates were interme-
diate to meropenem and resistant to ciprofloxacin, and only one
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was intermediate to ciprofloxacin and susceptible to meropenem.
Therefore, overall, 77, 85, and 160 isolates were susceptible, inter-
mediate, and resistant to meropenem, respectively, whereas 40, 1,
and 281 were susceptible, intermediate, and resistant to cipro-
floxacin, respectively. The mechanism of nonsusceptibility to
meropenemhad been recognized in 140 selected intermediate and
resistant isolates to be due to carbapenem-hydrolyzing activity, in
agreement with nationwide studies that showed that OXA-type
enzymes (OXA-24 [1, 14] specifically) are most prevalent in
Spain. The cause of nonsusceptibility to ciprofloxacin for 110 iso-
FIG 1 Three representative strains ofA. baumannii, incubatedwithmeropenem for 60min at 0g/ml (a, e, i) and at the 4-g/ml CLSI breakpoint concentration
of susceptibility (b, f, j), 8-g/ml CLSI breakpoint concentration of intermediate resistance (c, g, k), and 16-g/ml CLSI breakpoint concentration of resistance
(d, h, l). Bacteria were processed to determine effects on the cell wall, evaluated through nucleoid releasing after incubation with a specific lysing solution. (a
through d) Susceptible strain ATCC 19606 (MIC, 0.25 g/ml); (e through h) intermediate strain JC10/01 (pAT-RA-34s) (MIC, 8 g/ml); (i through l) resistant
strainRYC52763/97 producingOXA-24 (MIC, 256g/ml). Spreading of the nucleoidswas obvious in the susceptible strain after 4, 8, and 16g/ml but only after
8 and 16g/ml in the intermediate strain. A discrete background of extracellular DNA fragments was visualized in the meropenem-affected cultures. In spite of
susceptibility after 8 and 16 g/ml, a proportion of cells remained apparently unaffected, without nucleoid spreading, in the intermediate strain. The resistant
strain cells always maintained their morphological appearance.
FIG 2 Three representative strains of A. baumannii, incubated with ciprofloxacin for 40 min at 0 g/ml (a, e, i) and at the 1-g/ml CLSI breakpoint
concentration of susceptibility (b, f, j), 2-g/ml CLSI breakpoint concentration of intermediate resistance (c, g, k), and 4-g/ml CLSI breakpoint concentration
of resistance (d, h, l). Bacteria were processed to visualize the nucleoids, determining the presence or absence of chromosomal DNA fragmentation, i.e., diffused
DNA spots. (a through d) Susceptible strain ATCC 17978 (MIC,0.125g/ml); (e through h) intermediate strain (MIC, 2g/ml); (i through l) resistant strain
possessing both a gyrA Ser83 codonmutation (TCA¡TTA) and a parC Ser80 codonmutation (TCG¡TTG) (MIC, 64g/ml) (underlining indicates a changed
base). DNA fragmentation was evident in the susceptible strain after incubation with the drug at 1, 2, and 4 g/ml but only after incubation at 2 and 4 g/ml in
the intermediate strain. Nucleoids from the resistant strain never showed fragmentation.
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lates was established as the simultaneous mutations resulting in
changes at codon 83 for gyrA and at codon 80 for parC (10, 20, 21).
The susceptibility to meropenem and/or to ciprofloxacin was
always correctly identified by the assay. This was also the case for
resistance to the antibiotics. The only strain categorized as inter-
mediate to ciprofloxacin was exactly assigned by the assay. The
status of intermediate to meropenem attributed to 85 isolates ac-
cording to the CLSI criteria was similarly categorized by the assay
in 82 cases, the rest (3.5%) being visualized as resistant, thus pre-
venting the categorization as susceptible and the putative admin-
istration of carbapenems, whichmay cause a therapeutic failure. It
must be emphasized that meropenem-intermediate strains were
never detected as susceptible. Fifty isolates from the same study
were also examined for imipenem and levofloxacin susceptibility
or resistance. Results were fully coincident with those of mero-
penem or ciprofloxacin, following either CLSI criteria or the tech-
nical assay.
From a practical point of view, the clinician needs rapid,
straightforward information about the susceptibility or nonsus-
ceptibility of the isolate, in order to administer or not the appro-
priate antibiotic or to adequately assess the antibiotic treatment
after the administration of the initial empirical therapy. While
interesting to the microbiologist, the discrimination between in-
termediate or resistant classes should not modify the therapeutic
decision, which should initially tend to discard meropenem use.
Categorizing the isolates as susceptible or nonsusceptible using
the CLSI breakpoint of susceptibility supposes a 100% accuracy of
the assay. Thus, the technical handling of the procedure could be
even more simplified by incubating the isolate with the drug only
at the CLSI breakpoint concentration of susceptibility while si-
multaneously processing reliable susceptible, intermediate, and
resistant strains as assay controls.
The technical processing of antibiotic-treated bacteria takes 40
min, and visualization under fluorescence microscopy is rapid and
conclusive. Prior incubationwith the antibiotics was standardized to
60 min. Although 40 min is enough for quinolones, 60 min is better
for beta-lactams. This incubation time is estimated for bacteria expo-
nentially growing in broth cultures.When the bacteria come froman
agar plate, a 90-min incubation inMueller-Hinton broth prior to the
addition of carbapenem results inmore-homogeneous images of the
bacteria. This is due to the exponential growth of the whole popula-
tion at the moment of addition of the antibiotic.
Some extracellular DNA fragments are evident as background
in cultures of A. baumannii susceptible to meropenem during the
assay, without the necessity for a lysing step (Fig. 1) (18). Never-
theless, this background is variable, is usually very limited, and
sometimes may be present in cultures not subjected to incubation
with the antibiotic. Intermediate strains may or may not show the
extracellular DNA fragments. It is muchmore stringent to use the
lysing solution to assess the possible effect of meropenem, evalu-
ating the cell wall integrity through releasing of the nucleoid. The
presence of extracellular DNA fragments is a complementary but
not rigorous criterion.
The assay described here has been demonstrated to be a rapid,
simple, and reliable procedure to determine susceptibility or non-
susceptibility of clinical isolates of A. baumannii to carbapenems
and quinolones. Such a technique may have high clinical rele-
vance, given the major challenge to patient safety of this pathogen
and the critical importance of an appropriate antibiotic therapy as
early as possible to improve outcomes in vulnerable hospitalized
patients (7, 11, 13). An adequate early treatment also reduces the
length of hospital stay and health care costs. In the actual context
of reduction in the discovery and development of new antibiotics,
rational therapeutic strategies must aim to restrict the use of those
that aremost effective in order to avoid the emergence and spread-
ing of resistance (16). This could also be a potential benefit of the
assay. The procedure for rapid assessment of susceptibility or re-
sistance is going to be implemented for more antibiotic families,
not only in A. baumannii but also in other pathogens of high
clinical impact.
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